Positive preliminary data from the phase 1b/2 trial evaluating Olvi-Vec in small cell lung cancer have been announced.

The first patient has been dosed in the phase 3 TACTI-004 trial evaluating efti with Keytruda and chemotherapy for advanced ...

Systemic administration of Olvi-Vec in the initial dose escalation cohorts achieved a 71% disease control rate (5/7) with two partial responders. All participants with disease control experienced a ...

First patient safely dosed at Calvary Mater Newcastle Hospital in Australia, marking a significant milestone for ...

Targeted therapies have significantly improved outcomes for patients with non-small cell lung cancer (NSCLC) with actionable mutations. However, many tumors inevitably develop drug resistance and ...

One study showed small cell lung cancer (SCLC) tumors with higher DNA damage response (DDR) activity were initially more sensitive to chemotherapy but had worse overall survival.

Scientists found that aggressive lung cancer cells create their own electrical network, helping them spread. This unique ...

Small cell lung cancer (SCLC) is one of the most recalcitrant cancers. SCLC patients usually present with extensive ...

Lung cancer symptoms extend beyond respiratory issues and can manifest as shoulder pain. Tumors pressing on nearby nerves can ...

This review will focus on recent advances in our understanding of how these cells contribute to the tumor response to hypoxia in non-small-cell lung cancer. Lung cancer is the commonest cancer ...

Stage 4 non-small cell lung cancer (NSCLC) is the most advanced form of the condition and can be challenging to treat. Treatments include chemotherapy, surgery, immunotherapy, and radiotherapy.